Open-label Extension Study of ADP101
Public ClinicalTrials.gov record NCT05243719. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label Extension Study Evaluating the Safety and Efficacy of ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults (The Encore Study)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an open-label, safety extension study for participants who participated in the Harmony study (protocol ADP101-MA-01).
Study identification
- NCT ID
- NCT05243719
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 45 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 4 Years to 57 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 14, 2022 (Actual)
- Primary completion
- Feb 27, 2024 (Actual)
- Completion
- Feb 27, 2024 (Actual)
- Last update posted
- Mar 26, 2024
2022 – 2024
United States locations
- U.S. sites
- 14
- U.S. states
- 10
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Study Site | Mission Viejo | California | 92691 | — |
| Study Site | Rolling Hills Estates | California | 90274 | — |
| Study Site | San Diego | California | 92123 | — |
| Study Site | Colorado Springs | Colorado | 80907 | — |
| Study Site | Denver | Colorado | 80230 | — |
| Study Site | Tampa | Florida | 33620 | — |
| Study Site | Atlanta | Georgia | 30329 | — |
| Study Site | Marietta | Georgia | 30060 | — |
| Study Site | Normal | Illinois | 61761 | — |
| Study Site | Ann Arbor | Michigan | 48108 | — |
| Study Site | Chapel Hill | North Carolina | 27599 | — |
| Study Site | Cincinnati | Ohio | 45229 | — |
| Study Site | Charleston | South Carolina | 29420 | — |
| Study Site | Seattle | Washington | 98115 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05243719, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 26, 2024 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05243719 live on ClinicalTrials.gov.